Hanna Jarva

Hanna Jarva

Auto-generated profile, based on publicly available information

Hanna Jarva

HUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Finland; Translational Immunology Research Program and Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2007 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MLMatti Laine
Matti Laine
HJHanna Jarva
Hanna Jarva
SSSanna Seitsonen
Sanna Seitsonen
KHKarita Haapasalo
Karita Haapasalo
MLMarkus J. Lehtinen
Markus J. Lehtinen
SMSeppo K Meri
Seppo K Meri
Complement factor H (FH) is an important regulator of the alternative complement pathway. The Y402H polymorphism within the seventh short consensus repeat of FH was recently shown to be associated with age-related macular degeneration, the most common cause of irreversible blindness in the Western world. We examined the effects of this polymorphism on various FH functions. FH purified from sera of age-related macular degeneration patients homozygous for the FH402H variant showed a significantly reduced binding to C-reactive protein (CRP), an acute phase protein, as compared with FH derived from unaffected controls homozygous for the FH402Y variant. Strongly reduced binding to CRP was also observed with a recombinant fragment of FH (short consensus repeat 5–7) containing the same amino acid change. Because the interaction of CRP and FH promotes complement-mediated clearance of cellular debris in a noninflammatory fashion, we propose that the reduced binding of FH402H to CRP could lead to an impaired targeting of FH to cellular debris and a reduction in debris clearance and enhanced inflammation along the macular retinal pigmented epithelium-choroid interface in individuals with age-related macular degeneration.

1 December 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
NFNanna Fyhrquist
Nanna Fyhrquist
LRLasse Ruokolainen
Lasse Ruokolainen
ASAlina Suomalainen
Alina Suomalainen
SLSari Lehtimäki
Sari Lehtimäki
VVVille Veckman
Ville Veckman
HAHarri Alenius
Harri Alenius

1 August 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
AJAj Jääskeläinen
Aj Jääskeläinen
SKSuvi Kuivanen
Suvi Kuivanen
EKE Kekäläinen
E Kekäläinen
MAMj Ahava
Mj Ahava
RLR Loginov
R Loginov
MLM Lappalainen
M Lappalainen

15 December 2008 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
LDLivija Deban
Livija Deban
HJHanna Jarva
Hanna Jarva
MLMarkus J. Lehtinen
Markus J. Lehtinen
BBBarbara Bottazzi
Barbara Bottazzi
ABAntonio Bastone
Antonio Bastone
SMSeppo K Meri
Seppo K Meri
The long pentraxin PTX3 is a multifunctional soluble molecule involved in inflammation and innate immunity. As an acute phase protein, PTX3 binds to the classical pathway complement protein C1q, limits tissue damage in inflammatory conditions by regulating apoptotic cell clearance, and plays a role in the phagocytosis of selected pathogens. This study was designed to investigate the interaction of PTX3 with factor H (FH), the main soluble alternative pathway regulatory protein. We report that PTX3 binds FH with an apparent Kd of 1.1 × 10−7 M, and define two binding sites for PTX3 on FH. The primary binding site is located on FH domains 19–20, which interact with the N-terminal domain of PTX3, while a secondary binding site on domain 7 binds the glycosylated PTX3 pentraxin domain. The FH Y402H polymorphism, which affects binding to the short pentraxin CRP, did not affect binding to PTX3. Surface-bound PTX3 enhances FH recruitment and iC3b deposition and PTX3-bound FH retains its activity as a cofactor for factor I-mediated C3b cleavage. Thus, our findings identify PTX3 as a unique FH ligand in that it can bind both of the two hot-spots of FH, namely SCR7 and SCR19–20 and indicate that PTX3 participates in the localization of functionally active FH.

15 February 2002 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
HJHanna Jarva
Hanna Jarva
RJRobert Janulczyk
Robert Janulczyk
JHJens Hellwage
Jens Hellwage
PZPeter F. Zipfel
Peter F. Zipfel
LBLars BjörCk
Lars BjörCk
SMSeppo Meri
Seppo Meri
Streptococcus pneumoniae is an important cause of upper and lower respiratory tract infections, meningitis, peritonitis, bacterial arthritis, and sepsis. Here we have studied a novel immune evasion mechanism of serotype 3 pneumococci, which are particularly resistant to phagocytosis. On their surfaces the bacteria express the factor H-binding inhibitor of complement (Hic), a protein of the pneumococcal surface protein C family. Using radioligand binding, microtiter plate assays, surface plasmon resonance analysis, and recombinant constructs of factor H, we located the binding site of Hic to short consensus repeats (SCRs) 8–11 in the middle part of factor H. This represents a novel microbial interaction region on factor H. The only other ligand known so far for SCRs 8–11 of factor H is C-reactive protein (CRP), an acute phase protein that binds to the pneumococcal C-polysaccharide. The binding sites of Hic and CRP within the SCR8–11 region were different, however, because CRP did not inhibit the binding of Hic and required calcium for binding. Binding of factor H to Hic-expressing pneumococci promoted factor I-mediated cleavage of C3b and restricted phagocytosis of pneumococci. Thus, virulent pneumococci avoid complement attack and opsonophagocytosis by recruiting functionally active factor H with the Hic surface protein. Hic binds to a previously unrecognized microbial interaction site in the middle part of factor H.

1 October 1999 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
HJHanna Jarva
Hanna Jarva
TJT. Sakari Jokiranta
T. Sakari Jokiranta
JHJens Hellwage
Jens Hellwage
PZPeter F. Zipfel
Peter F. Zipfel
SMSeppo Meri
Seppo Meri
C-reactive protein (CRP) is a major acute phase protein whose functions are not totally clear. In this study, we examined the interaction of CRP with factor H (FH), a key regulator of the alternative pathway (AP) of complement. Using the surface plasmon resonance technique and a panel of recombinantly expressed FH constructs, we observed that CRP binds to two closely located regions on short consensus repeat (SCR) domains 7 and 8–11 of FH. Also FH-like protein 1 (FHL-1), an alternatively spliced product of the FH gene, bound to CRP with its most C-terminal domain (SCR 7). The binding reactions were calcium-dependent and partially inhibited by heparin. In accordance with the finding that CRP binding sites on FH were distinct from the C3b binding sites, CRP preserved the ability of FH to promote factor I-mediated cleavage of C3b. We propose that the function of CRP is to target functionally active FH and FHL-1 to injured self tissues. Thereby, CRP could restrict excessive complement attack in tissues while allowing a temporarily enhanced AP activity against invading microbes in blood.